Overview
Widely recognized as one of the country’s leading products liability and toxic torts defense firms, Hollingsworth LLP is regularly engaged at the forefront of critical litigation and “bet the company” cases. Representing clients from a broad range of industries, we were the first firm tapped by Monsanto/Bayer to defend its national Roundup litigation, including defending the first trial. We have also had substantial successes on their behalf in establishing the scientific parameters of the expert debate in the MDL and state consolidated litigation, in identifying and cultivating expert witnesses of international reputation, and in winning cases through litigation.
Demonstrating our expertise in trying such cases on behalf of manufacturers, suppliers, contractors, premises owners, waste generators, and other corporations, we appear in federal, state, and administrative tribunals, and have represented our clients in some of the leading appeals court cases involving toxics and products issues.
As national trial counsel for the defense of such cases involving serial litigation and cases consolidated in federal MDLs or state equivalents of MDLs, and in partnership with our national network of local counsel and experts, we have advanced our clients’ most sophisticated and technical defenses into all parts of the country.
DIVERSE, SIGNIFICANT REPRESENTATIONS
On the leading-edge of developments and trends in products liability and toxics law, we defend individual lawsuits, serial litigations, mass tort claims, and class actions alleging numerous personal injuries, property damage, and economic harm in connection with consumer product design, manufacture, and warnings; occupational or consumer exposure to allegedly toxic substances such as pesticides; and contamination from chemical, radioactive, and other hazardous substances. As a litigation-focused firm, we handle cases from the earliest pre-trial and investigative stages (including concurrent federal and/or state agency administrative, civil, and criminal investigations) through trial and resolution on appeal. As trials loom, we also have been engaged as lead counsel to take over from other firms and try critical or high-stakes cases.
Typical cases involve consumer products, alcohol, petroleum products and by-products, pesticides, solvents, detergents, radioactive materials, herbicides, asbestos-containing products, hazardous wastes, military hardware, “sick buildings,” various chemicals and chemical products, and their feedstocks and intermediates. (For more information related to our specialized work with pharmaceutical products and medical devices, see our Pharmaceutical Products & Medical Devices practice description.) These cases also regularly include novel or emerging plaintiffs’ theories in areas such as medical monitoring, second- or third-generation injury claims, synergistic interactions, hazardous substance migration, and disease “syndromes,” and frequently involve class action claims.
Working closely with world-class experts, we defend with a strongly science-based motions and trial practice, especially where plaintiffs allege that an occupational, environmental, or residential exposure (from air, property or groundwater contamination) caused chronic disease or sub-clinical injury. Having litigated several of the most significant pre- and post-Daubert toxics cases, we are relentless in our attack on junk science proponents who are willing to associate injury with exposure even to minuscule amounts of alleged toxins. Beginning with our successful trial defense of some of the earliest litigated toxic tort cases, we have developed considerable expertise and been particularly successful against plaintiffs alleging chemical carcinogenicity, leukemogenicity, immunosuppression, and other latent toxicities.
LITIGATION PLANNING AND ASSOCIATED REGULATORY COUNSELING
In an effort to minimize products liability and toxic tort exposure, we guide our clients in the following ways:
- proactively help our clients develop on-point business strategies
- track cases of interest for our clients’ amicus curiae participation, as well as draft and coordinate amicus curiae filings on their behalf
- work with clients to ensure worldwide insurance coverage and develop worldwide record retention programs
- screen product bulletins, labeling, distribution agreements, and media releases
- help clients confront national product recalls and corrective action programs, product boycotts, product bans, product modifications, and major published critiques
Our toxics and products liability work also involves the presentation of our clients’ positions at U.S. Congressional and state legislative proceedings and related counseling on pending and threatened legislation. This work includes alleged toxic exposures associated with the performance of government contracts—for example, alleged exposures to asbestos-containing products, pesticides and defoliants (Agent Orange) arising out of war contracts and alleged exposures to medical sterilants at a federal hospital—and extends into white-collar criminal defense.
FEDERAL AGENCY PROCEEDINGS
We have handled some of the largest matters before the Consumer Product Safety Commission, including successfully representing one of the major manufacturers of plastic pipe vent in connection with a national corrective action program involving mid-efficiency furnaces and boilers that resolved pending enforcement and class actions.
Drawing on our vast and complementary expertise in environmental law, we also have handled extensive proceedings before federal and state agencies including the U.S. Environmental Protection Agency and the U.S. Occupational Safety and Health Administration. As many of our clients are members of heavily regulated industries, we regularly advise them with respect to their dealings with governmental agencies and officials, especially as related to potential or actual tort liability.
Representative Cases
The Parlodel Trilogy
- Precedent
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- January 27, 2015
The Zometa Cases
- Precedent
- Class Action Defense
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- January 27, 2015
Court Dismisses $4B Claim Brought by New Mexico Against General Electric
- Precedent
- Environmental
- Natural Resource Damages
- Products Liability & Toxic Torts
- January 27, 2015
Federal Court Grants Daubert and SJ Motions to General Motors in PCB Lawsuit
- Precedent
- Environmental
- Products Liability & Toxic Torts
- October 1, 2006
Hollingsworth LLP Secures a 12(b)(6) Dismissal for Horizon Therapeutics USA, Inc.
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- October 28, 2024
Firm Client Monsanto Takes Step Forward in 11th Circuit Preemption Appeal
- Case
- Products Liability & Toxic Torts
- July 10, 2023
Hollingsworth LLP Obtains Partial Summary Judgment for Monsanto
- Case
- Products Liability & Toxic Torts
- June 14, 2023
Hollingsworth LLP Secures Daubert Victory on Behalf of Bayer
- Case
- Products Liability & Toxic Torts
- June 1, 2023
Hollingsworth LLP Secures Major Defense Verdict for Sterigenics and Sotera Health in Cook County, Ill. Trial
- Verdict
- Products Liability & Toxic Torts
- November 18, 2022
Firm Client Monsanto Secures Summary Judgment in Roundup Litigation
- Case
- Products Liability & Toxic Torts
- September 29, 2021
5th Circuit Affirms Novartis Summary Judgment in Tegretol Innovator Liability Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- February 5, 2021
Firm Secures Voluntary Dismissal with Prejudice for Novartis
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- June 29, 2020
Idaho State Court Rejects Innovator Liability Claims Against Novartis
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- September 25, 2019
Federal District Court Dismisses Putative Class Action Against Sherwin-Williams
- Case
- Environmental
- Products Liability & Toxic Torts
- August 21, 2018
Federal Court Holds N.J. Statute Precludes Punitive Damages and “fraud” Exception is Preempted
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- July 31, 2018
New Jersey Court Grants Avon Summary Judgment in Talc Litigation
- Case
- Class Action Defense
- Products Liability & Toxic Torts
- June 15, 2018
11th Circuit Affirms Summary Judgment in Reclast Case Based on Daubert Exclusion of Expert Testimony
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- April 30, 2018
Novartis Obtains Summary Judgment on Daubert Exclusion of Expert’s Testimony in Reclast Case
- Case
- Products Liability & Toxic Torts
- February 10, 2017
Pennsylvania Federal Court Grants Summary Judgment to Novartis in Personal Injury Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- October 7, 2015
Louisiana Court of Appeal Overturns Trial Court Judgment for Plaintiff
- Case
- Products Liability & Toxic Torts
- June 17, 2015
Alcon Secures Dismissal of Intraocular Lens Suit
- Case
- Complex Litigation
- Products Liability & Toxic Torts
- April 27, 2015
Seventh Circuit Affirms Summary Judgment for Alcon in Contact Lens Suit
- Case
- Complex Litigation
- Products Liability & Toxic Torts
- February 24, 2015
Based on California Statute of Limitations, Novartis Obtains Dismissal of Zometa Case for 2nd Time
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- August 19, 2014
Pennsylvania Federal Court Grants Summary Judgment in Aredia/Zometa Cases
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- July 28, 2014
Novartis Successfully Defeats Punitive Damages Claim in Aredia/Zometa Litigation
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- July 10, 2014
Novartis Gets Another Summary Judgment and Daubert Win Shortly Before Trial
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- July 2, 2014
Florida Court Dismisses Punitive Damages Claims in Aredia/Zometa Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- June 16, 2014
New Jersey Court Grants Novartis Summary Judgment in Bellwether Trial Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- June 6, 2014
5th Circuit Finds for Novartis, Affirming Dismissal of Aredia/Zometa Suit
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- May 27, 2014
North Carolina Federal Jury Returns Defense Verdict in Favor of Novartis
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- May 14, 2014
Novartis Prevails on Summary Judgment on Liability for Generic Products Manufactured by Others
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- May 12, 2014
Ninth Circuit Affirms Summary Judgment for Novartis
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- February 20, 2014
Novartis Wins Again
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- September 6, 2013
Arizona Federal Court Determines Novartis Warnings Adequate and Grants Summary Judgment
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- July 2, 2013
Western District of Oklahoma Grants Novartis Summary Judgment in Zometa Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- June 28, 2013
California Jury Returns Defense Verdict for Novartis
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- June 26, 2013
Louisiana Federal Court Grants Summary Judgment to Novartis After Excluding Plaintiff’s Expert Witnesses
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- June 14, 2013
New Jersey Jury Finds No Failure to Warn in Zometa Suit
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- May 15, 2013
S.D. Georgia Grants Novartis Summary Judgment in Zometa Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- May 15, 2013
Novartis Scores Unanimous Defense Verdict from Florida Jury
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- April 9, 2013
Novartis Wins Motion to Apply NJ Punitive Damages Law in Florida Pharma Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- February 7, 2013
Novartis Wins Summary Judgment in Rhode Island Aredia Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- December 19, 2012
Novartis Rebuts Plaintiff’s Changing Failure-to-Warn Theories, Obtaining Summary Judgment on Eve of Trial
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- November 16, 2012
E.D. of Washington Grants Summary Judgment to Novartis in Pharmaceuticals Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- October 2, 2012
Plaintiff Dismisses Case After Two and a Half Days of Trial
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- September 21, 2012
In Another Pharmaceutical Case, Novartis Wins Summary Judgment
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- September 19, 2012
In Major Precedent for Drugmakers, Federal Court Precludes Punitives Under New Jersey Law
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- September 5, 2012
Second Circuit Affirms Defense Verdict in Favor of Novartis
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- August 29, 2012
Western District of Oklahoma Grants Summary Judgment in for Novartis
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- July 18, 2012
E.D. Missouri Grants Novartis Summary Judgment in Products Liability Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- June 19, 2012
Novartis Bellwether Defense Verdict Upheld on Appeal in New Jersey
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- June 13, 2012
Federal Court in Pharma Litigation Excludes Most of Plaintiff’s Expert’s Proffered Testimony
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- March 21, 2012
Kentucky Jury Returns Unanimous Verdict for Novartis
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- January 31, 2012
Sandoz Exits MDL After E. D. New York Finds Product Liability Claims Preempted
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- January 30, 2012
Mississippi Supreme Court Follows Urging of American Coatings Association in Major Daubert Ruling
- Case
- Amicus
- Complex Litigation
- Products Liability & Toxic Torts
- September 8, 2011
Firm Secures Defense Verdict for Novartis in First Bellwether Aredia/Zometa Jury Trial
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- October 22, 2010
Southern District of Florida Upholds Removal of a “Pure Bill of Discovery” in Novartis Elidel Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- November 26, 2006
Norwood v. Raytheon Co., 237 F.R.D. 581 (W.D. Tex. 2006)
- Case
- Products Liability & Toxic Torts
- September 11, 2006
NLJ Top Defense Win for Firm in First Trial of Hernia Repair Mesh Serial Litigation
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- June 10, 2004
Clark v. Velsicol Chem. Corp., 944 F.2d 196 (4th Cir. 1991).
- Case
- Products Liability & Toxic Torts
- September 10, 1991
Insights & Events
Hollingsworth LLP Secures a 12(b)(6) Dismissal for Horizon Therapeutics USA, Inc.
news | November 4, 2024Robert Johnston and Eric Lasker Named to the 2025 Lawdragon 500 Leading Litigators in America
news | September 11, 2024Litigation and Compliance Impacts of Proposed Ethylene Oxide Regulations Based on Flawed Science
news | June 18, 2024Robert E. Johnston Speaks on Ethylene Oxide Litigation at DRI Toxic Torts & Environmental Law Seminar
event | March 22, 2024Following Illinois Trial Victory, Robert Johnston and Aleksandra Rybicki Publish on Ethylene Oxide (EO)
publication | July 28, 2023Firm Partners Robert Johnston and Matthew Malinowski Speak at NARTC’s 69th Annual Meeting
event | July 26, 2023Firm Client Lauded for Collaboration Conducting Trial Amid Pandemic in High-Profile Industrial Disaster
news | February 2, 2022Hollingsworth LLP Named to BTI’s “22 Best of the Best Law Firms in Product Liability Litigation”
news | November 10, 2021Law360: Monsanto Asks Georgia Supreme Court to Rule on Timeliness of Survival Actions
news | August 12, 2021Robert Johnston Speaks on Federal Preemption in Pharmaceutical Litigation at WLF Forum
news | June 10, 2021Hollingsworth LLP Conducts In-Person Civil Jury Trial Amid COVID-19 Pandemic
news | December 28, 2020Washington Legal Foundation & Atlantic Legal Foundation Support Bayer’s Challenge to California Court of Appeal Decision
news | August 4, 2020Hollingsworth LLP named 2018 U.S.Complex Litigation Law Firm of the Year and 2018 U.S.Pharmaceutical Products Liability Law Firm of the Year
news | June 21, 2018Hollingsworth LLP represents Monsanto in In Re:Roundup Products Liability Litigation in the Northern District of California.
By Kirby T. Grifffis for Washington Legal Foundation, March 2017
In Reclast case, Novartis obtains summary judgment based on Daubert exclusion of causation experts’ testimony.
news | February 10, 2017Mr. Griffis shares insights on his most recent victory, including trial tips.
And The Defense Wins: DRI’s The Voice recognizes Kirby Griffis in win for Novartis.
news | August 26, 2015Robert Johnston and Donald Fowler Selected Best in Pharmaceutical Products Liability Litigation-Washington, DC.
news | August 20, 2015Taking the “Product” Out of Product Liability: Litigation Risks and Business Implications of Innovator and Co-Promoter Liability
publication | July 15, 2015By Eric G. Lasker, Stephen A. Klein, and Tamara Fishman Barago for IADC's Defense Counsel Journal.
Partner Kirby T. Griffis represents Novartis in this matter.
Counsel, Know Thy Clients: Dismissals Under FRCP 25 for Failure to Properly Substitute for Deceased Plaintiffs
publication | February 27, 2015Hollingsworth LLP defends Ciba Vision Corp. in 7th Circuit Contact Lens Injury Suit
news | October 1, 2014Texas Supreme Court Rejects “Any Exposure” Causation in Asbestos Litigation
publication | August 1, 2014Effective Tactics for Opposing Certification from Recent Food Labeling Class Actions
publication | August 1, 2014For WLF Legal Backgrounder, by Firm partner Robert Johnston.
Fifth Circuit Puts an End to Texas Pharma Plaintiff’s California Dreamin’
publication | June 6, 2014Partner Eric Lasker's blog post on Washington Legal Foundation's The Legal Pulse
“The quest for the next ‘solvent bystander’ in asbestos litigation: Will Texas resume the search?”
publication | October 4, 2013Partner Eric G. Lasker discusses the present state of asbestos litigation in Texas and what could loom on the horizon since the Texas Supreme Court granted review in Bostic v. Georgia-Pacific Corp.
"After fewer than six hours of deliberations . . . the jury in Middlesex County Superior Court handed down its 7-1 decision in the case of Beverly Meng shortly after 11 a.m. Meng's lawsuit was the second to go on trial in the New Jersey mass tort, and Novartis has won both."
"A Florida federal judge on Wednesday nixed punitive damages from a lawsuit alleging Novartis Pharmaceuticals Corp.'s Aredia and Zometa bone drugs caused a woman to develop osteonecrosis of the jaw, finding that New Jersey law limiting punitive damages in such cases applies."
The New Jersey Supreme Court has declined to hear a challenge to judgments for Novartis Pharmaceuticals Corp. in the first bellwether trial in consolidated litigation over claims the drugmaker's bone cancer drugs Aredia and Zometa caused jaw deterioration.
In an article published in Law360, Hollingsworth LLP spotlights the ban on BPA in a growing number of states.
A Texas federal judge . . . ruled against a cancer patient who sued Novartis Pharmaceuticals Corp. over a jaw injury she allegedly sustained after taking Zometa, handing Novartis the latest of several wins in multidistrict litigation over the bone drug in the past several months.
Law360: Novartis Ruling Helps New Jersey Drug Companies Fend Off Punitive Damages
news | September 7, 2012A Maryland federal judge ruled Wednesday that a woman cannot pursue punitive damages under New Jersey law for an injury allegedly caused by Novartis Pharmaceuticals Corp. bone drugs because they are preempted by federal law, a decision that makes it more difficult for plaintiffs in product liability actions to seek such damages from New Jersey-based drugmakers, experts say.
There is No Place Like Home: The Defense Against Foreign Environmental Liaiblity Claims in U.S. Court Under the Alien Tort Statute
publication | February 1, 2012Partner Eric G. Lasker authors article for International Association of Defense Counsel Toxics & Hazardous Substances Litigation Committee Newsletter.
St. Louis Federal Jury Returns Verdict for Novartis in Second Zometa Defense Verdict in a Week
news | February 1, 2012Kapps v. Biosense Webster: Who Is Liable When a Reprocessed Medical Device Causes Injury?
publication | January 1, 2012A Washington Legal Foundation Working Paper, co-authored by Stephen A. Klein and Andrew L. Reissaus, this article discusses one of the first cases to address the application of traditional product liability theories in the context of a reprocessed medical device, in which both the original manufacturer and the reprocessor are defendants.
Hollingsworth LLP secures major defense verdict for client Novartis in federal Aredia®/Zometa® trial.
news | May 25, 2011A Defense Perspective on Excluding Corporate Conduct Experts in Product Liability Litigation
publication | May 19, 2011IADC's Toxic and Hazardous Substances Litigation Newsletter (Tamara Fishman, December 2010)
Joe Hollingsworth and Eric Lasker cited by 6th Circuit in Reversal of Plaintiff Verdict in Welding Fume Litigation
news | September 8, 2010Philadelphia Court of Common Pleas Grants Additional Forum Non Conveniens Dismissals Motions for General Electric in Gadolinium Cases.
news | September 1, 2010NJ Court Grants Summary Judgment on Direct-to-Consumer Advertising Claims before Trial in Zometa Litigation
news | September 1, 2010Court grants Firm client Novartis Pharmaceuticals Corporation summary judgment in case selected for first wave of trials in New Jersey Aredia® and Zometa® Mass Tort action.
news | April 12, 2010Eric Lasker Quoted in NLJ Article “D.C. Court of Appeals Resurrects Cell Phone Radiation Cases”
news | November 18, 2009The Consumer Product Safety Improvement Act, Its Implementation and Its Liability Implications
publication | July 1, 2009Defense Counsel Journal 76, No. 3 (July 2009)
Federal Court grants summary judgment filed by Firm client Novartis Pharmaceuticals Corporation in five suits brought by foreign plaintiffs.
news | February 2, 2009Judicial Panel on Multidistrict Litigation re-transfers two cases to Aredia®/Zometa® MDL over plaintiffs’ objections.
news | December 3, 2008Federal Court grants summary judgment based on product identification to Firm client Novartis Pharmaceuticals Corporation.
news | September 29, 2008Joe Hollingsworth and Kate Latimer author A Framework for Toxic Tort Litigation
publication | August 15, 2008Firm client Norfolk Southern Corporation reaches favorable agreement with Avondale Mills to settle claims from Graniteville accident.
news | July 2, 2008Rhode Island Supreme Court reverses and dismisses public nuisance verdict against former lead paint and pigment manufacturers.
news | July 1, 2008Hollingsworth LLP submits briefs in United States Supreme Court on behalf of two groups of Amici in Wyeth v. Levine.
news | June 4, 2008Building a Fire Wall: Missouri and New Jersey Hold the Line Against Plaintiffs’ Efforts to Expand the Law of Public Nuisance (part 2 of 2)
news | October 1, 2007Building a Fire Wall: Missouri and New Jersey Hold the Line Against Plaintiffs’ Efforts to Expand the Law of Public Nuisance (part 1 of 2)
publication | September 1, 2007LJN’s Product Liability Law & Strategy (September 2007) (Eric G. Lasker)
Former lead paint manufacturers prevail in Missouri Supreme Court, with an assist from Firm client, National Paint & Coatings Association.
news | June 12, 2007In the final installment, authors Joe Hollingsworth and Eric Lasker, discuss causation opinions premised on clinical practice, and how defense counsel can effectively use Daubert to exclude causation testimony that rests upon anecdotal case reports and clinical reasoning; Michigan Defense Quarterly (April 2007)
Written by Joe Hollingsworth and Eric Lasker, the second article explains how defense counsel can assist courts in properly applying the Daubert requirements to various categories of scientific evidence often cited by plaintiffs' experts in support of general causation opinions. Michigan Defense Quarterly (January 2007).
Throwing Out Junk Science: The first article of this 3-part series discusses the legal standards for admissibility of medical causation expert testimony following the Michigan Supreme Court's adoption of the federal Daubert requirements of reliance and relevance. Michigan Defense Quarterly (October 2006) (Joe G. Hollingsworth and Eric G. Lasker).
Andrew's Pharmaceutical Litigation Reporter (April 2006) (Eric G. Lasker)
Hollingsworth LLP Steps in as Appellate Counsel; 11th Circuit Vacates $18 million Verdict against GE
news | October 11, 2005Joe Hollingsworth and Eric Lasker Publish “Dodging Daubert” in Legal Times.
news | September 13, 2005The Case Against Differential Diagnosis: Daubert, Medical Causation Testimony, and the Scientific Method
publication | December 1, 2004Journal of Health Law (Winter 2004, Volume 37, No. 1) (Joe G. Hollingsworth and Eric G. Lasker)
LJN's Product Liability Law & Strategy (November/December 2004) (Kirby T. Griffis)
Joe Hollingsworth Highlighted in The American Lawyer for Pharmaceutical Litigation Victory
news | April 8, 2004Daubert v. Merrell Dow Pharmaceuticals, Inc.— An Essential Tool in Natural Resource Damages Litigation
publication | December 1, 2003ABA's Superfund and Natural Resource Damages Litigation Committee Newsletter (December 2003, Volume 1, No. 1, page 12) (Eric G. Lasker)
Case Reports Present Ample Potential for Scientific Fraud in Toxic Tort Cases
publication | August 18, 2003Expert Evidence Report, Vo. 3, No. 16 (August 2003)
VerdictSearch Products Liability Report (2003) (Gary I. Rubin)
ABA's The Brief (Winter 2002) (Eric G. Lasker)